转移性结直肠癌患者的健康相关生活质量及其与全身炎症反应和RAS、BRAF突变状态的关系
本研究在NORDIC-VII试验中评估西妥昔单抗对转移性结直肠癌患者健康相关生活质量(HRQoL)的影响,并分析HRQoL与RAS、BRAF突变状态及炎症生物标志物的关系。结果显示,化疗联合西妥昔单抗未影响HRQoL;BRAF突变患者基线及后续HRQoL较差;高血清白细胞介素-6或C反应蛋白患者HRQoL明显受损,且治疗期间IL-6和CRP水平下降与HRQoL改善显著相关。
要点
- 化疗联合西妥昔单抗未影响转移性结直肠癌患者的健康相关生活质量。
- BRAF突变患者基线及后续健康相关生活质量均较RAS突变或RAS/BRAF野生型患者差。
- 高血清白细胞介素-6或C反应蛋白患者健康相关生活质量明显受损。
核心结论
- 在转移性结直肠癌患者中,化疗联合西妥昔单抗未影响健康相关生活质量。
- BRAF突变肿瘤患者预后更差且健康相关生活质量更差。
- 全身炎症标志物水平与健康相关生活质量降低相关,提示患者可能从抗炎治疗中获益。
研究设计与样本
- 基于NORDIC-VII试验,评估西妥昔单抗对转移性结直肠癌患者健康相关生活质量的影响。
- 使用欧洲癌症研究与治疗组织生活质量问卷核心30(QLQ-C30)在基线、每第四个化疗周期后及治疗结束时评估健康相关生活质量。
- 对12个化疗周期内的健康相关生活质量进行时间趋势评估、治疗组间比较,并分析其与肿瘤突变状态及炎症标志物的关联。
主要发现
- 512例患者(90%)在治疗开始前完成QLQ-C30问卷。
- 基线时各治疗组健康相关生活质量变量均衡,治疗期间组间未见统计学显著差异。
- BRAF突变肿瘤患者基线及后续时间点的健康相关生活质量均较RAS突变或RAS/BRAF野生型肿瘤患者差。
- 高血清白细胞介素-6或C反应蛋白患者健康相关生活质量较正常水平患者明显受损。
- 治疗期间从基线至第4周期,白细胞介素-6和C反应蛋白水平下降与健康相关生活质量改善存在统计学显著关联。
关键数值与推荐
- QLQ-C30完成率:512例患者(90%)在治疗开始前完成。
- BRAF突变患者健康相关生活质量较RAS突变或RAS/BRAF野生型患者差。
- 高血清白细胞介素-6或C反应蛋白患者健康相关生活质量较正常水平患者明显受损。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to evaluate the effect of cetuximab on health-related quality of life (HRQoL) in the NORDIC-VII trial on metastatic colorectal cancer (mCRC), and to assess HRQoL in relation to RAS and BRAF mutation status and inflammatory biomarkers. PATIENT AND METHODS: HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) at baseline, after every fourth cycle of chemotherapy, and at the end of treatment. HRQoL during 12 cycles of chemotherapy was evaluated over time, compared between treatment arms, and assessed for association with tumour mutation status and inflammatory markers. RESULTS: QLQ-C30 was completed by 512 patients (90%) before start of treatment. HRQoL variables were well balanced across treatment arms at baseline, and no statistically significant differences during treatment were seen. Patients with BRAF-mutated tumours reported poorer HRQoL at baseline and subsequent time points than patients with RAS-mutated or RAS/BRAF wild-type tumours. Patients with high serum interleukin-6 (IL-6) or C-reactive protein (CRP) had markedly impaired HRQoL compared to patients with normal levels. There was a statistically significant association between reduction in IL-6 and CRP levels and improvement in HRQoL during treatment from baseline to cycle 4. CONCLUSION: The addition of cetuximab to chemotherapy did not affect HRQoL in mCRC patients. Patients with BRAF-mutated tumours have both a worse prognosis and a poor HRQoL. The associations between levels of systemic inflammatory markers and reduced HRQoL suggest that the patients might benefit from anti-inflammatory treatment.
引用
- Thomsen M, Guren MG, Skovlund E, et al. Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. Eur J Cancer. 2017. PMID: 28595137. doi:10.1016/j.ejca.2017.04.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。